e-OPRA Implant System for Lower Limb Amputees

NCT03720171 | Completed FDA Device

• 1 other identifier: IDE G170304
• Study Type: interventional
• Target: 2
• Locations: 1 country
• Sites: 1

Brief Summary

The e-OPRA Implant System, is a further development of the OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) Implant System, approved under HDE (Humanitarian Device Exemption) H080004. The e-OPRA Implant system is an implant system for direct skeletal anchorage of amputation prostheses. The added feature in the e-OPRA Implant system, is a bidirectional interface into the human body that allows permanent and reliable communication using implanted electrodes. These electrodes will provide long-term stable bioelectric signals for an improved control of the prosthetic limb. The purpose of the study is to evaluate the feasibility of a lower limb amputee with the e-OPRA Implant System exhibiting full neural control over a neuro-mechanical prosthetic system. A maximum of six subjects will be enrolled. Each subject will undergo a surgery where the e-OPRA Implant System will be implanted. The subjects will participate in follow-up sessions of which the last one occurs approximately 24 months after the surgery. This is a prospective, non-randomized, uncontrolled study.

Conditions

Amputation

Keywords

Osseointegration; Bone-anchored prosthesis; Neuro-prosthesis

Outcome Measures

Primary Outcomes (1)

• Electrode function

  i) To evaluate implantation robustness, and connector/lead integrity: i.a. Measured Impedance (kOhms) i.b. Maximal Voluntary Contraction (MVC) Amplitude (mV) ii) To evaluate sensor function and signal quality: ii.a. Signal-to-noise ratio (SNR) above 2

  24 months

Secondary Outcomes (1)

• Preferred walking speed

  24 months

Study Arms (1)

e-OPRA Implant System

EXPERIMENTAL

Implantation of e-OPRA Implant System in lower limb.

Device: e-OPRA Implant System

Interventions

e-OPRA Implant System DEVICE

Implantation of e-OPRA Implant System in lower limb to be used with amputation limb prosthesis

e-OPRA Implant System

Eligibility Criteria

• Age: 22 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or Female age 22-65 at the time of surgery.
• The patient must have a medical condition requiring performance of a unilateral transfemoral amputation with a minimum of 13 cm of residual femur after amputation, and:
• A: At a minimum level of amputation of 20 cm or greater above the knee joint line if physical therapy and prosthetist evaluation is commensurate with a standard K3 ambulatory status; or, B: At a minimum level of amputation of 16 cm above the knee joint line as part of a single-stage procedure if physical therapy and prosthetist evaluation is commensurate with a more active K3 or less active K4 postoperative ambulatory status.
• The subject must have undergone independent consultation with at least two lower extremity surgical specialists to ensure they have exhausted all limb salvage options prior to undergoing amputation, as well as a psychiatric evaluation to ensure appropriate capacity and volition.
• The patient must have the ability to ambulate at variable cadence (an expected lower extremity prosthesis functional level of K3 or above).
• The patient must have adequate bone stock to support the implanted device.
• In the opinion of the investigators, normal cognitive function and absence of any physical limitations, addictive diseases or underlying medical conditions that may preclude patient from being a good surgical and/or study candidate.
• Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study including the prescribed rehabilitation program.
• Written informed consent to participate in the study provided by the patient or legal representative.

You may not qualify if:

• Women who are pregnant, lactating or planning a pregnancy during the first twelve (12) months of the post-surgical follow-up.
• Subjects who have not been completely abstinent from tobacco use for at least 6 weeks preoperatively.
• Active infection or dormant bacteria.
• Subjects would have less than 2 mm of remaining cortex bone available around the implant, if implanted.
• Evidence of or a documented history of severe peripheral vascular disease, diabetes mellitus (type I or type II), skin diseases, Neuropathy or neuropathic disease and severe phantom pain, or osteoporosis, such that, in the opinion of the investigator, will not allow the subject to be a good study candidate.
• Evidence of any active skin disease involving the proposed surgical limb.
• History of systemically administered corticosteroids, immune-suppressive therapy or chemotherapy drugs within six (6) months of implant surgery.
• Severe co morbidity, atypical skeletal anatomy, or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, shortened life expectancy, vulnerable patient population, BMI \>40, etc.).
• The patient is currently involved in another clinical study where that participation may conflict or interfere with the treatment, follow-up or results of this clinical study.

Sponsors & Collaborators

• Integrum: lead
• Brigham and Women's Hospital: collaborator
• Massachusetts Institute of Technology: collaborator

Study Sites (1)

MIT Media Lab

Cambridge, Massachusetts, 02139, United States

Location

Study Officials

• Hugh M Herr, PhD

  Massachusetts Insititute of Technology

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Prospective, non-randomized, uncontrolled study.

Study Record Dates

• First Submitted: October 19, 2018
• First Posted: October 25, 2018
• Study Start: January 17, 2018
• Primary Completion: March 8, 2025
• Study Completion: March 8, 2025
• Last Updated: May 7, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)